MET and Mobius syndrome: A National Cancer Institute (NCI) sponsored phase I trial experiments with savolitinib, a small molecule inhibitor of c-Met (NCT03598244) in primary brain tumors including recurrent/refractory MBs with MET pathway activations, defined as MET mutations/amplifications/fusions, HGF amplifications, and gain of chromosome 7.